Glycosylation: a hallmark of cancer?

• Published in: Glycoconjugate journal Vol. 34; no. 2; pp. 147 - 156
• Main Authors: Vajaria, Bhairavi N., Patel, Prabhudas S.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.04.2017; Springer Nature B.V
• Subjects: Animals; Antigens; Antigens, Neoplasm - metabolism; Biochemistry; Biomarkers, Tumor - metabolism; Biomedical and Life Sciences; Cancer; Cellular biology; Glycosylation; Humans; Life Sciences; Matrix; Neoplasm Metastasis; Neoplasms - metabolism; Neoplasms - pathology; Pathology; Polysaccharides - metabolism; Review; Matrix metalloproteinases; Hallmarks; Glycosylation; E-cadherin; EGFR; Cancer; p53
• ISSN: 0282-0080; 1573-4986; 1573-4986
• DOI: 10.1007/s10719-016-9755-2

The hallmarks of cancer are characterized by functional capabilities that allow cancer cells to survive, proliferate and disseminate during the multistep tumorigenesis. Cancer being a cellular disease, changes in cellular glycoproteins play an important role in malignant transformation and cancer progression. The present review summarizes various studies that depicted correlation of glycosylation with tumor initiation, progression and metastasis, which are helpful in early diagnosis, disease monitoring and prognosis. The results are further strengthened by our reports, which depicted alterations in sialylation and fucosylation in different cancers. Alterations in glycosyltransferases are also involved in formation of various tumor antigens ( e.g. Sialyl Lewis x) which serves as ligand for the cell adhesion molecule, selectin which is involved in adhesion of cancer cells to vascular endothelium and thus contributes to hematogenous metastasis. Increased glycosylation accompanied by alterations in glycosyltranferases, glycosidases, glycans and mucins (MUC)s are also involved in loss of E-cadherin, a key molecule implicated in metastatic dissemination of cells. The present review also summarizes the correlation of glycosylation with all the hallmarks of cancer. The enormous progress in the design of novel inhibitors of pathway intermediates of sialylation and fucosylation can prove wonders in combating the dreadful disease. The results provide the evidence that altered glycosylation is linked to tumor initiation, progression and metastasis. Hence, it can be considered as a new hallmark of cancer development and strategies to develop novel glycosylation targeted molecules should be strengthened.